Serina Therapeutics, Inc. received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).
“November 22, 2022 we received a notification from the staff of the NYSE American (the “Exchange”) indicating that the Exchange has accepted a revised listing compliance plan from AgeX and has granted AgeX an extension of time to regain compliance with the Exchange’s continued listing standards as set forth in Section 1003(a)(i) and (ii) of the Exchange Company Guide by increasing our stockholders equity to not less than $4,000,000. The Exchange staff will periodically review our adherence to the plan milestones. If we are not in compliance with the continued listing standards by May 17, 2023”
Earnings Releases
Serina Therapeutics, Inc. reported financial results for the three months ended September 30, 2022.
“On November 10, 2022, AgeX issued a press release announcing its financial results for the three months ended September 30, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.